SPONSORED CONTENT
The implementation of Medicare’s Maximum Fair Price (MFP) program under the Inflation Reduction Act has introduced one of the most operationally significant changes to pharmaceutical reimbursement in decades, one that has important ramifications for 340B stakeholders. While the policy debate surrounding drug pricing reform has focused on affordability and manufacturer obligations, the first months of real-world execution reveal a different and equally important issue: the 340B’s industry’s operational infrastructure may not yet be prepared to support the complexity of large-scale price coordination, reconciliation, and dispute management.
Since January 2026, RxParadigm has supported health systems, federally qualified health centers (FQHCs), pharmacies, and other stakeholders participating in MFP effectuation through its Tungsten+PLUS™ platform. Originally developed as an end-to-end rebate administration and claims reconciliation platform, the technology has been adapted to support Medicare MFP workflows, including claims qualification, payment validation, overpayment management, dispute tracking, and reconciliation.
Because the platform processes operational data across multiple stakeholder groups — including covered entities (CEs), pharmacies, manufacturers, wholesalers, and third-party admininstrators (TPAs) — the emerging trends provide insight into how the MFP dispute environment is evolving.
Post-Payment Operational Model
One of the clearest observations from the first months of MFP implementation is that much of the current operational framework is centered on post-payment correction activities rather than front-end accuracy and validation.
When claims are overpaid, CEs are expected to self-report discrepancies through a third party vendor, generating future payment credits, and creating ongoing compliance tracking obligations. Operationally, this process is manageable, but it introduces administrative overhead and financial reconciliation requirements that many provider organizations were not structured to support at scale.
The more significant operational challenge emerges when claims are underpaid, denied incorrectly, or adjudicated using inaccurate pricing assumptions.
In many of these cases, CEs are asked to provide supporting documentation tied to specific wholesaler invoice numbers or to demonstrate eligibility through external systems and submissions. However, most CEs and pharmacies historically were not designed to map individual 340B purchases directly to wholesaler invoice identifiers at the claim level. As a result, organizations are developing new operational workflows to manually trace invoices, reconcile transactions, upload supporting documentation, and monitor dispute resolution outcomes.
This process can involve multiple disconnected systems, including wholesaler records, internal pharmacy data, 340B ESP submissions, TPAs, and manufacturer-directed inquiry processes. For organizations managing high specialty drug volumes across multiple dispensing channels, the administrative burden can become substantial.
Manufacturer Dispute Management Is Equally Fragmented
Manufacturers face a parallel operational challenge.
In many situations, duplicate discounts, overpayments, or inappropriate MFP adjudications are identified only after payment has already been issued. Manufacturers must then initiate Good Faith Inquiries or Administrative Dispute Resolution processes to recover or reconcile payments.
These activities often require challenging coordination across disparate data environments involving manufacturers, CEs, pharmacies, wholesalers, TPAs, Medicare Transaction Facilitator (MTF) data, and external reconciliation systems. This creates a fragmented operational landscape with limited centralized visibility into dispute status, documentation standards, or consistent reconciliation methodologies.
The first months of implementation demonstrated how quickly dispute volumes can scale under these conditions.
RxParadigm’s January 2026 analysis observed that approximately 40% of MFP claims experienced incorrect adjudication during the program’s first month, including duplicate payments, inappropriate denials, or incorrect pricing determinations. While subsequent months have shown some improvement, the disputes remain highly active and resource intensive for all stakeholders.
There are now tens of thousands of prescriptions that manufacturers initially denied for payment and that have subsequently been disputed by pharmacy providers as improper denials. While the volume alone highlights the growing administrative and operational complexity of the dispute process, our data indicate that the issue may be substantially larger. Based on an average denial rate of approximately 18% during the same period, the potential scale of improperly denied claims could translate into millions of prescriptions industrywide. Many of these challenges are not necessarily policy failures. Rather, they reflect how the health care ecosystem relies on disconnected operational systems that were never designed to coordinate real-time eligibility validation, discount qualification, and multi-party reconciliation at this level of complexity.
Implications for Future 340B Rebate-Based Models
Current policy discussions often assume that shifting from upfront discounts to rebate administration may simplify duplicate discount management. However, early MFP implementation suggests that retrospective rebate reconciliation introduces substantial operational demands — particularly when supported by fragmented data systems and inconsistent validation methodologies.
If rebate-based models expand without standardized claim qualification rules, interoperable infrastructure, and centralized reconciliation capabilities, the industry risks creating an even larger environment of disputes, invoice matching challenges, duplicate discount investigations, and post-payment recovery efforts.
The lesson emerging from MFP implementation is clear: large-scale reimbursement reform requires operational infrastructure that prioritizes prevention, transparency, and real-time coordination — not simply retrospective correction mechanisms.
Growing Importance of Pre-Validation and Neutral Clearinghouse Infrastructure
As the industry adapts to the evolving 340B and MFP landscape, there is growing recognition that a neutral clearinghouse infrastructure may play a critical role in future program administration. Equally important is the need for systems capable of pre-validating claims as part of an end-to-end operational process that addresses the needs of all stakeholders while minimizing operational weak points and downstream disputes.
Platforms capable of integrating claims data, wholesaler activity, pharmacy dispensing records, manufacturer policies, and payment reconciliation workflows into a unified operational environment can significantly reduce fragmentation and improve visibility across the entire claim lifecycle.
A neutral infrastructure is particularly important because it provides a shared operational framework that is not exclusively controlled by manufacturers, covered entities, or any single stakeholder group. This structure can support greater trust, transparency, standardization, interoperability, and operational consistency across the ecosystem.
RxParadigm’s Tungsten+PLUS platform was designed with this objective in mind — supporting front-end claim pre-validation and end-to-end operational workflows across MFP effectuation, 340B rebate administration, dispute management, audit readiness, duplicate discount prevention, and reconciliation within a centralized and compliance-ready environment.
Conclusion
The first months of MFP implementation have demonstrated that operational execution may become the defining factor for long-term success of drug pricing reform.
The core challenge facing the industry is whether it can establish scalable, interoperable, and transparent infrastructure to manage increasingly complex reimbursement coordination across manufacturers, providers, pharmacies, wholesalers, and regulators.
The current dispute environment offers an important early signal.
Without a pre-validation mechanism or standardized operational frameworks and centralized reconciliation capabilities, the administrative burden for MFP and future 340B rebate models may expand, increasing friction, cost, and financial uncertainty for all.
While the MTF payment module has improved and succeeded in processing and issuing payments within required timelines, timely claims payment should be viewed as an expectation rather than an achievement. Claims adjudication technology has existed for over four decades, and the industry has demonstrated the ability to move transactions efficiently at scale. Establishing an operational payment framework for MFP remains an important early milestone. The long-term success of MFP and any future 340B rebate-based framework will depend not only on policy design, but on whether the operational infrastructure can support trusted, sustainable execution across manufacturers, CEs, pharmacies, wholesalers, and regulators alike.
Mesfin Tegenu is CEO and Chairman of RxParadigm. He can be reached at Mesfin.Tegenu@rxparadigm.com.
